2Steg PG,James SK,Atar D,et al.ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation.Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology(ESC)[J].Eur Heart,2012,33(20):2569-2619.
3O'Gara PT,Kushner FG,Ascheim DD,et al.2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction:A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J].Coll Cardiol,2013,61(4):e78-e140.
4Huxtable LM,Tafreshi MJ,Rakkar AN.Frequency and management of thrombocytopenia with the glycoprotein IIb/IIIa receptorantagonists[J].Cardiol,2006,97(3):426-429.
5Elcioglu OC,Ozkok A,Akpinar TS,et al.Severe thrombocytopenia and alveolar hemorrhage represent two types of bleeding tendency during tirofibantreatment:case report and literature review[J].Hematol,2012,96(3):370-375.
6Aster RH,Curtis BR,Bougie DW,et al.Scientific and Standardization Committee of The International Society On Thrombosis and Haemostasis.Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors:position paper of the ISTH working group onthrombocytopenia and GPIIb/IIIa inhibitors[J].Thromb Haemost,2006,4(3):678-679.
8Hamm CW,Bassand JP,Agewall S,et al.ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent T-segment elevation.The task force for the management of acute coronary syndromes(ACS)in patients presenting without persistent ST-segment elevation of the European Society of Cardiology(ESC)[J].Eur Heart,2011,32(23):2999-3054.
9Eke HU,Teke D.Profound thrombocytopenia related with tirofiban:Will it be enough to only stop medicine?[J].Platelets,2013,24(4):335-337.
二级参考文献6
1Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS),European Association for Percutaneous Cardiovascular Interventions (EAPCI),Wijns W. Guidelines on myocardial revascularization[J].European Heart Journal,2010.2501-2555.
2Levine GN,Bates ER,Blankenship JC. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention:a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the society for cardiovascular angiography and interventions[J].Circulation,2011.e574-e651.
3Hillis LD,Smith PK,Anderson JL. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery.A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines.developed in collaboration with the American Association for Thoracic Surgery,Society of Cardiovascular Anesthesiologists,and Society of Thoracic Surgeons[J].Journal of the American College of Cardiology,2011.e123-e210.
4Nashef SA,Roques F,Michel P. European system for cardiac operative risk evaluation (EuroSCORE)[J].European Journal of Cardio-Thoracic Surgery,1999.9-13.
5Serruys PW,Morice MC,Kappetein AP. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease[J].New England Journal of Medicine,2009.961-972.
6Peterson ED,Dai D,DeLong ER. Contemporary mortality risk prediction for percutaneous coronary intervention:results from 588,398 procedures in the Natio Cardiovascular Data Registry[J].Journal of the American College of Cardiology,2010.1923-1932.
